Literature DB >> 6693767

The cytotoxic effector cells in preparations of adherent mononuclear cells from human peripheral blood.

B Freundlich, G Trinchieri, B Perussia, R B Zurier.   

Abstract

We have characterized the effector cells present in fresh adherent cell preparations from human peripheral blood that are responsible for the lysis of K562 and IgG antibody-sensitized P815Y target tumor cells. Purified lymphocytes and monocytes, separated from adherent cell preparations by using techniques that utilized light scatter properties and reactivity of the cells with monoclonal antibodies, were used as effectors for the spontaneous and antibody-dependent cytotoxicity. The role of monocytes was also studied at the single cell level. Our results indicate that when a subpopulation of adherent cells that is B73.1+ (NK cells), B44.1- (non-monocyte), with light scatter characteristics of lymphocytes, is removed from the total adherent cell population, the resultant purified monocytes are unable to spontaneously kill K562 target cells. This data suggests that fresh unstimulated adherent cell cytotoxicity against K562 cells is mediated by lymphocyte contamination in these preparations and that the cell responsible for this killing is probably the NK cell. In contrast antibody-dependent cellular cytotoxicity against P815Y target cells is mediated by monocytes and lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6693767

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Transcriptional and posttranscriptional regulation of tumor necrosis factor gene expression in human monocytes.

Authors:  E Sariban; K Imamura; R Luebbers; D Kufe
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

2.  Lactoferrin-inducible monocyte cytotoxicity for K562 cells and decay of natural killer lymphocyte cytotoxicity.

Authors:  J A McCormick; G M Markey; T C Morris
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

3.  Natural killer cell function is not diminished in the healthy aged and is proportional to the number of NK cells in the peripheral blood.

Authors:  G J Ligthart; H R Schuit; W Hijmans
Journal:  Immunology       Date:  1989-11       Impact factor: 7.397

4.  Human leukocytes kill varicella-zoster virus-infected fibroblasts in the presence of murine monoclonal antibodies to virus-specific glycoproteins.

Authors:  M Ito; T Ihara; C Grose; S Starr
Journal:  J Virol       Date:  1985-04       Impact factor: 5.103

5.  Binding of fibrinogen to human monocytes.

Authors:  D C Altieri; P M Mannucci; A M Capitanio
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

6.  Monocyte-mediated drug-dependent cellular cytotoxicity: effects on different WEHI 164 target cell lines.

Authors:  R Austgulen; O Kildahl-Andersen; T Espevik
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

7.  Induction of in vitro autoimmune responses by mononuclear blood cells in Hashimoto's thyroiditis.

Authors:  S A Stern; P C Dau
Journal:  Clin Exp Immunol       Date:  1987-09       Impact factor: 4.330

8.  Autologous tumor killing and natural cytotoxic activity of tumor-associated macrophages in cancer patients.

Authors:  E Yanagawa; A Uchida; M Moore; M Micksche
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

9.  Human monocyte-derived macrophages and dendritic cells as targets for biomaterial cytocompatibility studies using an improved in vitro culture system.

Authors:  E Mebouta-Nkamgueu; J J Adnet; D Ittelet; D Laurent-Maquin; S Bouthors; G Potron; M Guenounou; J Bernard
Journal:  J Mater Sci Mater Med       Date:  2001-04       Impact factor: 3.896

10.  Phenotype of peripheral blood lymphocytes in patients with progressive systemic sclerosis: activated T lymphocytes and the effect of D-penicillamine therapy.

Authors:  B Freundlich; S A Jimenez
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.